Ibrutinib premix

Category API

Details	Specifications
CAS Number	936563-96-1
Molecular Formula	C25H24N6O2
Molecular Weight	440.50 g/mol.
Synonyms	(R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one
Chemical Name	1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
Common name	Ibrutinib
Therapeutic use	Ibrutinib acts as a Bruton's tyrosine kinase (BTK) inhibitor, treating blood cancers like Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), and Waldenström's macroglobulinemia. It slows or stops cancer cell growth, and can treat chronic graft-versus-host disease
Background	Ibrutinib (marketed as Imbruvica) is a first-in-class, oral, targeted covalent inhibitor of Bruton’s tyrosine kinase (BTK). It was developed to treat B-cell malignancies, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), by blocking the signaling pathways that B-cells need to survive and proliferate
Grade	In-house
Polymorph	Form-C
GTI	Risk assessment report available
Nitrosamines	Risk assessment report available
DMF Availability	Available
Manufacturing batch size	100.0 Kg
Production capacity	Annual capacity is 5 – 6 tonnes
Stability data	Available

Please Note: We partner exclusively with pharmaceutical manufacturers, biotech companies, and international trading firms. Minimum order quantities apply*

Disclaimer:

The information provided on this webpage is based on the best available knowledge at the time of publication; however, accuracy and completeness are not guaranteed. Product specifications may change without notice. It is the responsibility of the purchaser or user to verify suitability and compliance. This product is intended for research use only and is not approved for human consumption.

Why Shilpa Pharma?

Happy Customers

Projects Successfully Completed

Established

PhD Experts Driving R&D Excellence

Team Size

World-Class API Manufacturing Sites

Global Audits Successfully Completed

Comprehensive CDMO Service Offerings

Our Ibrutinib premix are also Available for

Questions & Answers

FAQ on Ibrutinib premix

Everything You Need to Know About Shilpa Pharma

Shilpa Pharma – Your Trusted Global CDMO Partner

Delivering end-to-end solutions across API oncology, generics, peptides, polymers and specialty chemicals, we empower partners to accelerate development, ensure compliance, and reach markets faster with reliable, cost-effective innovation.